{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:40Z","timestamp":1787026600203,"version":"build-2736575974"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201700003C, R00AI138860 , R01AI167724 , R01AI116698"],"award-info":[{"award-number":["HHSN272201700003C, R00AI138860 , R01AI167724 , R01AI116698"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Use of adeno-associated virus (AAV) vectors is complicated by host immune responses that can limit transgene expression. Recent clinical trials using AAV vectors to deliver HIV broadly neutralizing antibodies (bNAbs) by intramuscular administration resulted in poor expression with anti-drug antibodies (ADA) responses against the bNAb.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Here we compared the expression of, and ADA responses against, an anti-SIV antibody ITS01 when delivered by five different AAV capsids. We first evaluated ITS01 expression from AAV vectors three different 2A peptides. Rhesus macaques were selected for the study based on preexisiting neutralizing antibodies by evaluating serum samples in a neutralization assay against the five capsids used in the study. Macaques were intramuscularly administered AAV vectors at a 2.5x10^12 vg\/kg over eight administration sites.  ITS01 concentrations and anti-drug antibodies (ADA) were measured by ELISA and a neutralization assay was conducted to confirm\n                      <jats:italic>ex vivo<\/jats:italic>\n                      antibody potency.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We observed that ITS01 expressed three-fold more efficiently in mice from AAV vectors in which heavy and light-chain genes were separated by a P2A ribosomal skipping peptide, compared with those bearing F2A or T2A peptides. We then measured the preexisting neutralizing antibody responses against three traditional AAV capsids in 360 rhesus macaques and observed that 8%, 16%, and 42% were seronegative for AAV1, AAV8, and AAV9, respectively. Finally, we compared ITS01 expression in seronegative macaques intramuscularly transduced with AAV1, AAV8, or AAV9, or with the synthetic capsids AAV-NP22 or AAV-KP1. We observed at 30 weeks after administration that AAV9- and AAV1-delivered vectors  expressed the highest concentrations of ITS01 (224 \u00b5g\/mL, n=5, and 216 \u00b5g\/mL, n=3, respectively). The remaining groups expressed an average of 35-73 \u00b5g\/mL. Notably, ADA responses against ITS01 were observed in six of the 19 animals. Lastly, we demonstrated that the expressed ITS01 retained its neutralizing activity with nearly the same potency of purified recombinant protein.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Overall, these data suggest that the AAV9 capsid is a suitable choice for intramuscular expression of antibodies in nonhuman primates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2023.1105617","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T06:53:44Z","timestamp":1682060024000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["A strategy for high antibody expression with low anti-drug antibodies using AAV9 vectors"],"prefix":"10.3389","volume":"14","author":[{"given":"Meredith E.","family":"Davis-Gardner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse A.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Pekrun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim L.","family":"Weisgrau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"Furlott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva G.","family":"Rakasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Farzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-041015-055515","article-title":"Broadly neutralizing antibodies to HIV and their role in vaccine design","volume":"34","author":"Burton","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.712122","article-title":"Broadly neutralizing antibodies for HIV-1 prevention","volume":"12","author":"Walsh","year":"2021","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00908-15","article-title":"Broadly neutralizing human immunodeficiency virus type 1 antibody gene transfer protects nonhuman primates from mucosal simian-human immunodeficiency virus infection","volume":"89","author":"Saunders","year":"2015","journal-title":"J Viro"},{"key":"B4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nature14264","article-title":"AAV-expressed eCD4-ig provides durable protection from multiple SHIV challenges","volume":"519","author":"Gardner","year":"2015","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005090","article-title":"AAV-delivered antibody mediates significant protective effects against SIVmac239 challenge in the absence of neutralizing activity","volume":"11","author":"Fuchs","year":"2015","journal-title":"PloS Pathogens"},{"key":"B6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/nm.3471","article-title":"Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission","volume":"20","author":"Balazs","year":"2014","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nature10660","article-title":"Antibody-based protection against HIV infection by vectored immunoprophylaxis","volume":"481","author":"Balazs","year":"2011","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.immuni.2019.02.005","article-title":"Adeno-associated virus delivery of anti-HIV monoclonal antibodies can drive long-term virologic suppression","volume":"50","author":"Martinez-Navio","year":"2019","journal-title":"Immunity"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1967","article-title":"Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys","volume":"15","author":"Johnson","year":"2009","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00449","article-title":"Long-term delivery of an anti-SIV monoclonal antibody with AAV","volume":"11","author":"Martinez-Navio","year":"2020","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30003-7","article-title":"Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial","volume":"6","author":"Priddy","year":"2019","journal-title":"Lancet HIV"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.01.004","article-title":"Anti-drug antibody responses impair prophylaxis mediated by AAV-delivered HIV-1 broadly neutralizing antibodies","volume":"27","author":"Gardner","year":"2019","journal-title":"Mol Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5409","article-title":"AAV-delivered eCD4-ig protects rhesus macaques from high-dose SIVmac239 challenges","volume":"11","author":"Gardner","year":"2019","journal-title":"Sci Trans Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/mt.2015.191","article-title":"Host anti-antibody responses following adeno-associated virus\u2013mediated delivery of antibodies against HIV and SIV in rhesus monkeys","volume":"24","author":"Martinez-Navio","year":"2016","journal-title":"Mol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1007395","DOI":"10.1371\/journal.ppat.1007395","article-title":"Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge","volume":"14","author":"Welles","year":"2018","journal-title":"PloS Pathogens"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01762-x","article-title":"Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial","volume":"28","author":"Casazza","year":"2022","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"17158","DOI":"10.1073\/pnas.0909520106","article-title":"Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors","volume":"106","author":"Lu","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.10.053","article-title":"Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques","volume":"34","author":"Greig","year":"2016","journal-title":"Vaccine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.06.001","article-title":"Bioengineered viral platform for intramuscular passive vaccine delivery to human skeletal muscle","volume":"10","author":"Paulk","year":"2018","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.131610","article-title":"Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors","volume":"4","author":"Pekrun","year":"2019","journal-title":"JCI Insight"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1008351","article-title":"Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells","volume":"7","author":"Chng","year":"2015","journal-title":"MAbs"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1087","article-title":"Stable antibody expression at therapeutic levels using the 2A peptide","volume":"23","author":"Fang","year":"2005","journal-title":"Nat Biotechnol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018556","article-title":"High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice","volume":"6","author":"Kim","year":"2011","journal-title":"PLOS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112268","article-title":"Intramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression","volume":"9","author":"Greig","year":"2014","journal-title":"PloS One"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.03.029","article-title":"5 year expression and neutrophil defect repair after gene therapy in alpha-1 antitrypsin deficiency","volume":"25","author":"Mueller","year":"2017","journal-title":"Mol Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix644","article-title":"Intramuscular adeno-associated virus\u2013mediated expression of monoclonal antibodies provides 100% protection against Ebola virus infection in mice","volume":"217","author":"van Lieshout","year":"2018","journal-title":"J Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1172\/JCI68205","article-title":"CpG-depleted adeno-associated virus vectors evade immune detection","volume":"123","author":"Faust","year":"2013","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.74.18.8358-8367.2000","article-title":"Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120","volume":"74","author":"Derdeyn Cynthia","year":"2000","journal-title":"J Viro"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.4.2855-2864.1998","article-title":"Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1","volume":"72","author":"Platt Emily","year":"1998","journal-title":"J Viro"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00709-09","article-title":"Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1","volume":"83","author":"Platt Emily","year":"2009","journal-title":"J Viro"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01726-08","article-title":"Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research","volume":"82","author":"Takeuchi","year":"2008","journal-title":"J Viro"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1896-1905.2002","article-title":"Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy","volume":"46","author":"Wei","year":"2002","journal-title":"Antimicrobial Agents Chemother"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/s41467-021-22654-7","article-title":"Modification of n-terminal \u03b1-amine of proteins via biomimetic ortho-quinone-mediated oxidation","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.omtm.2022.01.003","article-title":"High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypes","volume":"24","author":"Gardner","year":"2022","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2022.081","article-title":"Seroprevalence of AAV neutralizing antibodies in males with duchenne muscular dystrophy","author":"Verma","year":"2022","journal-title":"Hum Gene Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/9780471729259.mc14d01s26","article-title":"Production and discovery of novel recombinant adeno-associated viral vectors","volume":"26","author":"Mueller","year":"2012","journal-title":"Curr Protoc Microbiol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"10108","DOI":"10.1128\/JVI.79.16.10108-10125.2005","article-title":"Human immunodeficiency virus type 1 env clones from acute and early subtype b infections for standardized assessments of vaccine-elicited neutralizing antibodies","volume":"79","author":"Li","year":"2005","journal-title":"J Viro"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00803-16","article-title":"CD4-induced antibodies promote association of the HIV-1 envelope glycoprotein with CD4-binding site antibodies","volume":"90","author":"Gardner","year":"2016","journal-title":"J Viro"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1105617\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T06:53:48Z","timestamp":1682060028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1105617\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2023.1105617"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1105617","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"article-number":"1105617"}}